Navigation Links
GeNO LLC Makes Significant Additions to Management Team to Increase Capability and Talent

COCOA, Fla., Jan. 19, 2012 /PRNewswire/ -- GeNO LLC (, a privately held, advanced development-stage technology company, today announced the hiring of four new senior executives as well as two promotions. The additions add significant management talent and capability to the company.

In a series of moves that more than doubles GeNO's executive management team, the company today announced the hiring of:

  • Kurt Dasse, Ph.D., former President and Founder of recently-sold Levitronix LLC, as Executive Vice President. Dasse has spent nearly three decades conducting research in cardiovascular disorders and developing and commercializing medical devices, including products to treat heart and renal failure. He has written more than 100 journal articles, multiple book chapters, and holds several patents.
  • Jack Whiting, former Vice President, General Counsel of Levitronix LLC, as Vice President of Operations. Whiting will be responsible for finance, legal, human resources and risk management functions, as well as supply chain management.
  • Daniel O'Donnell, former Vice President, Business Development at L-3 CyTerra, as General Manager. O'Donnell will be responsible for managing daily operations and new R&D business pursuits.
  • Ed Bromberg, Ph.D., previously at L-3 CyTerra and Thermo, as R&D Manager. Bromberg brings more than 34 years of experience in the development of scientific instrumentation from concept to release to production.

GeNO has promoted:

  • Robert Roscigno, Ph.D. to Executive Vice President. Roscigno is a seasoned executive with a unique combination of clinical development, sales, marketing and business expertise in the pharmaceutical industry. He has over 16 years of drug development experience covering inhaled, I.V., subcutaneous and oral products, including 14 years in the Pulmonary Hypertension space.
  • Lucas Gamero, Ph.D. to Vice President of R&D. Gamero has 15 years of experience in research and new product development in the medical device and pharmaceutical industry.

"As our trials progress and our unique technology reach important milestones, it is important for us to expand our talent pool in product development, research and operations. We have done so with very well-respected, experienced leaders in their fields," said GeNO LLC Founder and President David Fine, Ph.D. "NITROSYL™ is an opportunity to impact an area of multiple diseases that need treatment options, and our management team growth adds to our commitment."

GeNO is currently developing a unique nitric oxide generation and delivery technology named NITROSYL™ that will help address the cost, complexity and lack of portability of current inhaled nitric oxide treatment regimens for a multitude of diseases, and would potentially reach a much larger group of patients. GeNO is developing three nitric oxide delivery platforms: a stand-alone gas cylinder system for hospital and outpatient use, a ventilator-based platform for Intensive Care Unit use, and a flashlight-sized ambulatory system for chronic outpatient use. The company is currently performing two Phase 2 trials: one, as a Pilot Study in Pulmonary Arterial Hypertension (PAH) and a second dose-escalation trial for the Treatment of Pulmonary Hypertension in patients with PAH and Pulmonary Hypertension secondary to Idiopathic Pulmonary Fibrosis (PH-IPF). Additional study details can be found on -- Identifiers NCT01092559 and NCT01265888. 

ABOUT GENO LLC                                           
GeNO LLC, founded in 2006, is a privately held, advanced development-stage technology company that is developing innovative nitric oxide (NO) generation and delivery platforms to enable the true potential of inhaled nitric oxide to be realized. The company is focused on applying the new technology to deliver inhaled nitric oxide to patients in a wide variety of settings, including ambulatory and in-home use for potential chronic treatment. GeNO's NITROSYL Systems will be regulated by the FDA as new drugs with their own NDAs. These systems have been designated as Combination Products by the FDA Office of Combination Products, with the Division of Cardiovascular and Renal Products designated as the lead reviewer for GeNO's initial INDs.

Media Contacts:


Carla Burigatto, 610-457-2178

Alexandra Paparsenos, 301-792-6019


Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. The Lancet Makes Research More Accessible for Healthcare Professionals With New App for iPad
2. As Released on 30 December, 2011: Novogen Modifies ADR Program and Makes Further Investment Into Marshall Edwards
3. Technology makes storing radioactive waste safer
4. MaxWest Environmental Systems Makes Commitment to Clinton Global Initiative
5. Generex Makes Podium Presentation of Clinical Data on Generex Oral-lyn™ at European Association for the Study of Diabetes Annual Meeting
6. Catalyst that makes hydrogen gas breaks speed record
7. Nanotechnology makes big inroads into construction industry
8. Activated graphene makes superior supercapacitors for energy storage
9. Abaxis Makes $2.8 Million Equity Investment in Scandinavian Micro Biodevices APS
10. Charging makes nano-sized electrodes swell, elongate and spiral
11. Clarient Tender Offer Extended; Clarient Makes Additional Disclosures to Settle Litigation
Post Your Comments:
(Date:6/23/2016)... WA (PRWEB) , ... June 23, 2016 , ... ... announces the release of its second eBook, “Clinical Trials Patient Recruitment and Retention ... recruitment and retention in this eBook by providing practical tips, tools, and strategies ...
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
(Date:6/23/2016)... A person commits a crime, and the detective ... the criminal down. An outbreak of foodborne illness ... (FDA) uses DNA evidence to track down the bacteria that ... It,s not. The FDA has increasingly used a complex, cutting-edge ... illnesses. Put as simply as possible, whole genome sequencing is ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... Plate® YM (Yeast and Mold) microbial test has received AOAC Research Institute approval ... of microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory ...
Breaking Biology Technology:
(Date:6/15/2016)... New York , June 15, 2016 /PRNewswire/ ... a new market report titled "Gesture Recognition Market by ... and Forecast, 2016 - 2024". According to the report, ... USD 11.60 billion in 2015 and is estimated ... reach USD 48.56 billion by 2024.  ...
(Date:6/7/2016)... 7, 2016  Syngrafii Inc. and San Antonio ... that includes integrating Syngrafii,s patented LongPen™ eSignature "Wet" ... collaboration will result in greater convenience for SACU ... while maintaining existing document workflow and compliance requirements. ... Highlights: ...
(Date:6/2/2016)... --  The Weather Company , an IBM Business (NYSE: ... in which consumers will be able to interact with IBM ... voice or text and receive relevant information about the product ... have long sought an advertising solution that can create a ... and valuable; and can scale across millions of interactions and ...
Breaking Biology News(10 mins):